Answer
ER-positive, HER2-negative locally advanced or metastatic breast cancer carrying an activating ESR1 mutation after progression on endocrine-based treatment.
Sources for this answer
- Inluriyo 200 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 1